Abraxane and Alimta in Advanced Solid Tumors

Breast Cancer Clinical Trial

Official title:

Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00470548
• Other study ID #: UCDCC#185
• Secondary ID: 224355ABX027H3E-
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: May 3, 2007
• Last updated: January 5, 2018
• Start date: April 2007
• Est. completion date: October 2014

Study information

• Verified date: January 2018
• Source: University of California, Davis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel albumin-stabilized nanoparticle formulation together with pemetrexed may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with pemetrexed and to see how well they work in treating patients with advanced non-small cell lung cancer, breast cancer, or other solid tumors.

Description:

OBJECTIVES:

Primary

• Determine the safety of paclitaxel albumin-stabilized nanoparticle formulation when administered with pemetrexed disodium in patients with advanced non-small cell lung cancer, breast cancer, or other solid tumors. (Phase I)

• Determine the efficacy of this regimen, as measured by objective tumor response rate (RECIST criteria), in these patients. (Phase II)

Secondary

• Determine the preliminary efficacy of paclitaxel albumin-stabilized nanoparticle formulation and pemetrexed disodium in these patients. (Phase I)

• Determine the overall survival of patients treated with this regimen. (Phase II)

• Evaluate the frequency and severity of toxicities associated with this regimen. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of paclitaxel albumin-stabilized nanoparticle formulation followed by an open-label, phase II study.

• Phase I: Patients receive pemetrexed disodium IV over 10 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of paclitaxel albumin-stabilized nanoparticle formulation until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

• Phase II: Patients receive pemetrexed disodium and paclitaxel albumin-stabilized nanoparticle formulation at the MTD as in phase I.

After completion of study treatment, patients are followed periodically.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 49
• Est. completion date: October 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. For the phase II portion patients must have cytologically or histologically proven selected stage IIIB (pleural effusion) or IV NSCLC.

2. For the phase II portion patients must have NSCLC that has progressed or recurred after treatment with platinum-based therapy.

3. No prior pemetrexed. Prior Taxol is allowed. Prior ABI 007 is not allowed.

4. Patients must have measurable disease by RECIST criteria for the phase II portion.

5. Patients must be 18 years of age or older.

6. Patients must have a performance status of 0 -2

7. Patients must have an estimated survival of at least 3 months.

8. Any prior chemotherapy must have been completed at least 4 weeks prior to start of treatment.

9. Patients must have adequate renal function as documented by a calculated creatinine clearance of > 45 ml/min

10. Patients must have adequate liver functions: AST and ALT < 2.5 X upper limit of normal, and bilirubin < upper limit of normal.

11. Patients must have adequate bone marrow function: Platelets >100,000 cells/mm3 and ANC > 1,500 cells/mm3.

12. For patients who have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing.

13. Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) may be included if they are neurologically stable and have been off steroids and anticonvulsants for at least 4 weeks.

14. Patients must be able to take and retain oral medication.

15. Ability to take folic acid, vitamin B12 and dexamethasone according to protocol.

16. Ability to interrupt NSAIDS 2 days before, the day of, and 2 days following administration of pemetrexed.

17. Patients of reproductive potential must agree to use effective contraceptive method while on treatment and for 3 months afterwards as the effects of these drugs on the unborn fetus are unknown.

18. No other current active malignancy.

19. Patient or his/her legally authorized representative or guardian signed the Informed Consent form prior to participation in any study-related activities.

Exclusion Criteria

1. Pregnant or breastfeeding women.

2. Patient with pre-existing peripheral neuropathy of NCI CTCAE Version 3.0 of grade 2.

3. Patient has a clinically significant concurrent illness.

4. Patient is currently enrolled in a different clinical study in which investigational procedures are performed or investigational therapies are administered.

5. Patient has a history of allergy or hypersensitivity to the study drugs or a taxane.

6. Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.

7. Prior therapy with pemetrexed, or ABI-007.

8. Patient is receiving treatment with any excluded concomitant medication.

9. Presence of third space fluid which cannot be controlled by drainage.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Lung Neoplasms
• Unspecified Adult Solid Tumor, Protocol Specific

Intervention

Drug:
• Abraxane
ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
• Alimta
Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)

Locations

Country	Name	City	State
United States	University of California Davis Cancer Center	Sacramento	California

Sponsors (3)

Lead Sponsor	Collaborator
University of California, Davis	Celgene, Eli Lilly and Company

Country where clinical trial is conducted

United States, 

References & Publications (1)

Ho C, Davies AM, Sangha RS, Lau D, Lara P Jr, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec;31 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Dose Limiting Toxicities	Dose limiting toxicity (DLT) was defined as any of the following occurring during the first cycle: Grade 4 thrombocytopenia, or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion, febrile neutropenia, neutropenia with documented infection. Non-hematologic DLT included any other = grade 3 non-hematologic toxicity that was clinically significant and considered by the investigator to be related to study drug. Alopecia and grade 3 allergic reaction/hypersensitivity with infusion were not considered DLTs.	Up to21 days
Primary	Number of Patients With Toxicities	Toxicities was evaluated based on the standard NCI CTCAE Version 3.0 grading criteria. Attributable grade = 3 hematologic and non-hematologic toxicities are presented here.	Up to 1 year
Secondary	Duration of Overall Survival	From time of enrollment to the first observation of disease progression or death.	Up to 2 years
Secondary	Number of Participants With Complete Response	Per RECIST criteria, complete response (CR) is defined as the disappearance of all target lesions.	Up to 2 years
Secondary	Number of Participants With Stable Disease	Stable Disease is measured from the start of the treatment until the criteria for disease progression are met. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	Up to 2 years
Secondary	Number of Participants With Partial Response	At least a 30% decrease in the sum of the longest diameter of target lesions	Up to 2 years
Secondary	Number of Participants With Disease Control	Disease control is complete response plus partial response plus stable disease from the start of treatment to death or disease progression.	Up to 2 years